Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults |
| |
| Institution: | 1. Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Queensland, Australia;2. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia;3. WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia;4. Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales Australia, Sydney, New South Wales, Australia;5. Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia;6. Immune Therapies Laboratory, Burnet Institute, Victoria, Australia;7. Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University, Australia;1. MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA;2. Naval Medical Research Unit No. 6, Lima, Peru;1. Department of Family Medicine, Semmelweis University, Budapest, Hungary;2. University of Debrecen, Hungary;1. Department of Molecular and Medical Virology, Ruhr-University Bochum, Germany;2. Ichor Medical Systems, Inc., San Diego, CA, USA;3. Universitätsklinikum Erlangen, Institute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany;1. Laboratoire Colloïdes et Matériaux Divisés’ (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, F-75005 Paris, France;2. Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, D-CHAB, ETH Zürich, Zürich, Switzerland;1. The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK;2. Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA;3. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA;4. Department of Medicine and Immunology, Duke University School of Medicine, Durham, NC 27710, USA;5. International Research Center for Medical Sciences, Kumamoto University, Kumamoto 860-0811, Japan |
| |
| Abstract: | BackgroundSeasonal influenza vaccination with a standard trivalent influenza vaccine (TIV) induces a modest, and cross-reactive, Fc functional antibody response in older adults. Recent improvements to influenza vaccines include a quadrivalent influenza vaccine (QIV) and a TIV adjuvanted with the squalene-based oil-in-water emulsion MF59.MethodsPre- and post-vaccination serum samples from older adults vaccinated with QIV (n = 27) and adjuvanted TIV (n = 44) were studied using hemagglutination inhibition (HAI) assays and dimeric Fc-gamma receptor IIIa binding ELISAs, as a surrogate of antibody-dependent cellular cytotoxicity (ADCC).ResultsWe found that the unadjuvanted QIV elicited a stronger HAI response against the H1N1 vaccine virus than the adjuvanted TIV. Post-vaccination levels of HA-specific ADCC antibodies were similar for older adults vaccinated with QIV and adjuvanted TIV. The ADCC response to influenza vaccination was largely determined by pre-vaccination or baseline levels of these antibodies, with older adults with low baseline levels of ADCC activity demonstrating greater post-vaccination rises.ConclusionsIn this cohort of community-dwelling older adults, the QIV was at least as good as the adjuvanted TIV in the induction of ADCC and HAI responses. Further studies on how these antibody responses translate to efficacy in preventing influenza infections are warranted. |
| |
| Keywords: | Influenza vaccine Inactivated influenza vaccine Adjuvanted influenza vaccine Hemagglutination inhibition Antibody-dependent cellular cytotoxicity Fc receptor Older adults |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
